来那度胺在套细胞淋巴瘤中的活性可由自然杀伤细胞介导的细胞毒性解释
研究基于CC-5013-MCL-002试验(NCT00875667)的临床样本,比较来那度胺单药与研究者选择单药治疗,并在套细胞淋巴瘤临床前模型中验证。结果显示来那度胺应答者自然杀伤细胞占总淋巴细胞比例较无应答者显著增加,且与无进展生存和总生存延长趋势相关。来那度胺主要通过增强自然杀伤细胞介导的细胞毒性发挥作用,对套细胞淋巴瘤细胞的直接细胞毒性作用极小。
要点
- 来那度胺应答者自然杀伤细胞占总淋巴细胞比例较无应答者显著增加。
- 该增加与无进展生存和总生存延长的趋势相关。
- 来那度胺增强自然杀伤细胞介导的细胞毒性,直接细胞毒性作用极小。
核心结论
- 来那度胺在套细胞淋巴瘤中的临床活性主要由免疫介导机制解释,即增强自然杀伤细胞介导的细胞毒性。
研究设计与样本
- 研究分析CC-5013-MCL-002试验(NCT00875667)入组患者的临床样本,该试验比较来那度胺单药与研究者选择单药治疗,并在套细胞淋巴瘤临床前模型中验证发现。
主要发现
- 来那度胺应答者自然杀伤细胞占总淋巴细胞比例较无应答者显著增加,且与无进展生存和总生存延长趋势相关。
- 来那度胺的临床应答与基线肿瘤微环境中其分子靶点cereblon的表达无关,也与 reported 影响布鲁顿酪氨酸激酶抑制剂伊布替尼临床应答的基因突变无关。
- 临床前实验显示来那度胺通过增加溶解性免疫突触形成和颗粒酶B分泌增强自然杀伤细胞对套细胞淋巴瘤细胞的细胞毒性。
- 来那度胺对套细胞淋巴瘤细胞的直接细胞毒性作用极小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this observed clinical activity, the mechanism of action (MOA) of lenalidomide has not been characterized in this setting. We investigated the MOA of lenalidomide in clinical samples from patients enrolled in the CC-5013-MCL-002 trial (NCT00875667) comparing single-agent lenalidomide versus investigator's choice single-agent therapy and validated our findings in pre-clinical models of MCL. Our results revealed a significant increase in natural killer (NK) cells relative to total lymphocytes in lenalidomide responders compared to non-responders that was associated with a trend towards prolonged progression-free survival and overall survival. Clinical response to lenalidomide was independent of baseline tumour microenvironment expression of its molecular target, cereblon, as well as genetic mutations reported to impact clinical response to the Bruton tyrosine kinase inhibitor ibrutinib. Preclinical experiments revealed lenalidomide enhanced NK cell-mediated cytotoxicity against MCL cells via increased lytic immunological synapse formation and secretion of granzyme B. In contrast, lenalidomide exhibited minimal direct cytotoxic effects against MCL cells. Taken together, these data provide the first insight into the clinical activity of lenalidomide against MCL, revealing a predominately immune-mediated MOA.
引用
- Hagner PR, Chiu H, Ortiz M, et al. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. Br J Haematol. 2017. PMID: 28771673. doi:10.1111/bjh.14866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。